



Effective Date:
Monday, July 08, 2019

Test Updates

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, July 08, 2019

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.



Effective Date:
Monday, July 08, 2019

Test Updates

Test Code	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0718B	Brivaracetam, Blood							•	
0718SP	Brivaracetam, Serum/Plasma							•	
3036U	Methyltin, Urine			•	•				



Test Updates

Test Changes

0718B Brivaracetam, Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Brivaracetam
Method (CPT Code)

Compound Name	Units	Reference Comment
Brivaracetam	mcg/mL	The recommended steady-state brivaracetam plasma concentration for seizure control is 0.2 to 2.0 mcg/mL. The blood to plasma ratio is approximately 0.6.

0718SP Brivaracetam, Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Brivaracetam
Method (CPT Code)

Compound Name	Units	Reference Comment
Brivaracetam	mcg/mL	The recommended steady-state brivaracetam plasma concentration for seizure control is 0.2 to 2.0 mcg/mL.

3036U Methyltin, Urine

Summary of Changes: Specimen Requirements were changed.
Specimen Requirements (Specimen Container) were changed.
Specimen Requirements (Rejection Criteria) were changed.
Stability was changed.

Specimen Requirements: 12 mL Urine
 Transport Temperature: Frozen
 Specimen Container: Plastic container (preservative-free)
 Light Protection: Not Required
 Special Handling: None
 Rejection Criteria: Received Room Temperature. Received Refrigerated.
 Stability: Room Temperature: 2 day(s)
 Refrigerated: 2 day(s)
 Frozen (-20 °C): 14 day(s)